Literature DB >> 3969240

Ovarian carcinoma: a multivariate analysis of prognostic factors.

K D Swenerton, T G Hislop, J Spinelli, J C LeRiche, N Yang, D A Boyes.   

Abstract

Five hundred and fifty six women with invasive epithelial ovarian carcinoma were assessed for postoperative treatment between 1966 and 1976. The records of this group were reviewed retrospectively. Sixteen characteristics of the patient and tumor were analyzed for prognostic significance by univariate and multivariate techniques. Tumor grade, the presence of residual disease, and patient performance status are identified as stage-specific independent prognostic factors. These independent factors define patient subsets with good, intermediate, and poor prognosis within each stage. The results show that more effective treatment strategies are required for patients in poor prognosis subsets. Estimates of tumor grade, extent of residual disease, and performance status should be included in reports of treatment outcome.

Entities:  

Mesh:

Year:  1985        PMID: 3969240

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  24 in total

Review 1.  Survivorship as an element of clinical trials in ovarian cancer.

Authors:  Jessica N McAlpine; Lari B Wenzel
Journal:  Int J Gynecol Cancer       Date:  2011-05       Impact factor: 3.437

2.  Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response.

Authors:  Yu-Li Chen; Ming-Cheng Chang; Chia-Yen Huang; Ying-Cheng Chiang; Han-Wei Lin; Chi-An Chen; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Oncol       Date:  2011-12-20       Impact factor: 6.603

3.  Extent of apoptosis in ovarian serous carcinoma: relation to mitotic and proliferative indices, p53 expression, and survival.

Authors:  M E McMenamin; A J O'Neill; E F Gaffney
Journal:  Mol Pathol       Date:  1997-10

4.  Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.

Authors:  Mark S Carey; Roshan Agarwal; Blake Gilks; Kenneth Swenerton; Steve Kalloger; Jennifer Santos; Zhenlin Ju; Yiling Lu; Fan Zhang; Kevin R Coombes; Dianne Miller; David Huntsman; Gordon B Mills; Bryan T Hennessy
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

5.  Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer.

Authors:  Changqing Zhao; Loganath Annamalai; Changfa Guo; Narasimhan Kothandaraman; Stephen Chee Liang Koh; Huoming Zhang; Arijit Biswas; Mahesh Choolani
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

6.  Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.

Authors:  K D Swenerton; J L Santos; C B Gilks; M Köbel; P J Hoskins; F Wong; N D Le
Journal:  Ann Oncol       Date:  2010-08-06       Impact factor: 32.976

7.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

8.  Fertility preservation in patients with early epithelial ovarian cancer.

Authors:  Yong-Soon Kwon; Ho-Suap Hahn; Tae-Jin Kim; In-Ho Lee; Kyung-Taek Lim; Ki-Heon Lee; Jae-Uk Shim; Jung-Eun Mok
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

9.  A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age.

Authors:  Hiroaki Kajiyama; Mika Mizuno; Kiyosumi Shibata; Tomokazu Umezu; Shiro Suzuki; Eiko Yamamoto; Hiroko Mitsui; Ryuichiro Sekiya; Kaoru Niimi; Michiyasu Kawai; Tetsuro Nagasaka; Fumitaka Kikkawa
Journal:  Int J Clin Oncol       Date:  2013-12-05       Impact factor: 3.402

Review 10.  Considerations in the surgical management of ovarian cancer in the elderly.

Authors:  Carrie Langstraat; William A Cliby
Journal:  Curr Treat Options Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.